Select a Region
North America

Browsing Archive: ImmuneImmune | EVERSANA

EVERSANA
Posted on 9月 20, 20239/20/23

A Systematic Literature Review and Network Meta-Analysis of Therapies for Psoriatic Arthritis on Patient-reported Outcomes

EVERSANA
Posted on 2月 1, 20232/1/23

Cost effectiveness of Ofatumumab in Comparison With Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

EVERSANA
Posted on 2月 1, 20232/1/23

Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review

EVERSANA
Posted on 2月 1, 20232/1/23

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis

EVERSANA
Posted on 2月 1, 20232/1/23

Matching-Adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40

EVERSANA
Posted on 1月 25, 20231/25/23

Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder

EVERSANA
Posted on 10月 2, 202010/2/20

Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

EVERSANA
Posted on 10月 2, 202010/2/20

Network Meta-Analysis of Ulcerative Colitis Pharmacoptherapies: Carryover Effects from Induction and Bias of the Results

EVERSANA
Posted on 10月 2, 202010/2/20

Methodological challenges with conducting network meta-analyses assessing long-term comparative efficacy in psoriasis: A critique of assumptions underpinning recent indirect treatment comparisons

EVERSANA
Posted on 10月 2, 202010/2/20

Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis

Immune